The FDA’s June 9 drug approvals bring new preventive options for infants at risk of RSV, innovative combination …
The FDA’s June 9 drug approvals bring new preventive options for infants at risk of RSV, innovative combination …
Significant biotech advancements and industry collaborations define early June with a focus on live biotherapeutics, liquid biopsies, and …
Early clinical successes, new research on immune toxicities, and expanding partnerships underscore the evolving landscape of cell and …
Adding atezolizumab to FOLFOX chemotherapy after surgery boosts disease-free survival in patients with surgically resected mismatch repair deficient …
Big pharma pursues targeted expansion while trials in radiopharmaceuticals and immunotherapy highlight the breadth of innovation across cancer, …
A large phase III study known as SERENA-6 is attracting wide attention for challenging the way resistance is …
In the UK DANTE trial stopping immunotherapy at 12 months produces disease control rates comparable to two-year treatment …
U.S. regulators expand treatment options in prostate cancer as biotech innovators TRexBio and Spinogenix push forward with immune …
New pivotal trial milestones in multiple sclerosis and head and neck cancer, plus key collaboration and funding moves, …
Landmark ATOMIC trial shows combining immunotherapy and chemo improves outcomes for colon cancer patients with mismatch-repair deficiency
Already a subscriber? Log in